Malaria breakthrough triggers hope for new vaccine

Malaria breakthrough triggers hope for new vaccine 

Scientists in Scotland say they have found a link to various strains of a malaria parasite, potentially paving the way for the next-generation malaria drug or vaccine development. 


http://www.pharmaceutical-technology.com/news/newsmalaria-breakthrough-triggers-hope-for-new-vaccine?WT.mc_id=DN_News

Japanese researchers have created a supramolecule that binds to cyanide ions in a similar way to the blood protein haemoglobin. This could pave the way for faster, more effective cyanide antidotes.

The supramolecule mimics the structure of haemoglobin (below) with iron(III) at it's centre
CREDIT© Wiley-VCH


http://www.rsc.org/chemistryworld/2013/05/haemoglobin-mimic-mops-cyanide-poisoning

DRUGS-Using FTIR and NIR spectroscopy in process control

http://www.manufacturingchemist.com/technical/article_page/Using_FTIR_and_NIR_spectroscopy_in_process_control/88634




BY WORLD DRUG TRACKER
DR ANTHONY CRASTO

Improving Compound Extraction Efficiency Novel Method for Skin Tissues Allows Higher-Throughput Sample Processing

READ ALL AT
http://www.genengnews.com/gen-articles/improving-compound-extraction-efficiency/4888/





BY WORLD DRUG TRACKER
DR ANTHONY CRASTO

First BRCA Targeted Drug Shows Early Promise, BioMarin Jumping to Phase III Trials

First BRCA Targeted Drug Shows Early Promise, BioMarin Jumping to Phase III ...

Medical Daily

Although the aim of the Phase I/II trial was to evaluate the maximum tolerated dose (MTD) and the secondary aim was to evaluate safety and preliminary effects of the drug, the positive clinical results are pushing the company to pursue Phase III ...
http://www.medicaldaily.com/articles/16129/20130603/brca-target-brca-mutation-biomarin-drug-breast-cancer-ovarian-cancer.htm



BY WORLD DRUG TRACKER
DR ANTHONY CRASTO

New Muscular Dystrophy Drugs Offer Hope

New Muscular Dystrophy Drugs Offer Hope

Wall Street Journal

A drug called ataluren is in phase 3 testing, after showing mixed results in earlier studies. Its maker, PTC Therapeutics Inc., declined to comment because it has filed to go public. Pfizer Inc. says it is in phase 1 testing of an antibody that aims to ...


BY WORLD DRUG TRACKER
DR ANTHONY MELVIN CRASTO

GlaxoSmithKline recently announced data from a phase III trial its oncology drug, Votrient (pazopanib). This trial evaluated the use of Votrient as maintenance therapy in women suffering from epithelial ovarian, fallopian tube or primary peritoneal cancer,

Glaxo Reports Votrient Data - Analyst Blog

NASDAQ

GlaxoSmithKline  recently announced data from a phase III trial (n = 940) evaluating its oncology drug, Votrient (pazopanib). The randomized, double-blind, placebo-controlled phase III trial evaluated the use of Votrient as maintenance therapy in women suffering from epithelial ovarian, fallopian tube or primary peritoneal cancer,

http://www.nasdaq.com/article/glaxo-reports-votrient-data-analyst-blog-cm250408


BY WORLD DRUG TRACKER
DR ANTHONY MELVIN CRASTO